Kathmere Capital Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $527K | Sell |
7,539
-1,751
| -19% | -$122K | 0.04% | 265 |
|
|
2025
Q1 | $683K | Buy |
9,290
+4,232
| +84% | +$311K | 0.06% | 191 |
|
|
2024
Q4 | $331K | Sell |
5,058
-1,162
| -19% | -$76.1K | 0.03% | 298 |
|
|
2024
Q3 | $485K | Buy |
6,220
+719
| +13% | +$56K | 0.05% | 212 |
|
|
2024
Q2 | $429K | Buy |
5,501
+1,436
| +35% | +$112K | 0.05% | 197 |
|
|
2024
Q1 | $275K | Buy |
4,065
+175
| +4% | +$11.9K | 0.03% | 246 |
|
|
2023
Q4 | $262K | Sell |
3,890
-1,255
| -24% | -$84.5K | 0.03% | 226 |
|
|
2023
Q3 | $348K | Buy |
5,145
+292
| +6% | +$19.8K | 0.05% | 168 |
|
|
2023
Q2 | $347K | Buy |
4,853
+358
| +8% | +$25.6K | 0.05% | 148 |
|
|
2023
Q1 | $312K | Buy |
4,495
+72
| +2% | +$5K | 0.05% | 148 |
|
|
2022
Q4 | $300K | Buy |
4,423
+53
| +1% | +$3.59K | 0.05% | 144 |
|
|
2022
Q3 | $240K | Sell |
4,370
-425
| -9% | -$23.3K | 0.05% | 138 |
|
|
2022
Q2 | $317K | Sell |
4,795
-565
| -11% | -$37.4K | 0.06% | 116 |
|
|
2022
Q1 | $356K | Buy |
+5,360
| New | +$356K | 0.06% | 109 |
|
|
2021
Q4 | – | Sell |
-4,028
| Closed | -$242K | – | 140 |
|
|
2021
Q3 | $242K | Buy |
+4,028
| New | +$242K | 0.04% | 129 |
|
|
2021
Q1 | – | Sell |
-1,611
| Closed | -$81K | – | 149 |
|
|
2020
Q4 | $81K | Hold |
1,611
| – | – | 0.02% | 202 |
|
|
2020
Q3 | $88K | Buy |
+1,611
| New | +$88K | 0.02% | 190 |
|